24
Oct
2023

INABATA France

Exhibitor at CPHI Barcelona 2023 stand 81B60, API
About Us

With more than 40 years of history in API manufacturing, PHARMASYNTHESE belongs to the Japanese Group INABATA through its French subsidiary INABATA France.GMP Manufacturing and Distribution of:- Active Pharmaceutical Ingredients- Advanced Intermediates- Specialities

  • FR
  • 2015
    On CPHI since
  • 2
    Certificates
  • 25 - 49
    Employees
Company types
Manufacturer/Innovator
Primary activities
API Producer
Contact info
  • 6-8, Rue du 4 Septembre, Immeuble Le Rubix, Issy-Les-Moulineaux, 92130 , Wissous, France
Event information
CPHI Barcelona 2023
  • 24-26 October 2023
  • Fira Barcelona Gran Via, Spain
  • Visit us at stand 81B60, API

Products Featured at CPHI Barcelona 2023

  • SERTACONAZOLE NITRATE

    Product SERTACONAZOLE NITRATE

    PHARMASYNTHESE - INABATA offers a wide range of products which includes Sertaconazole Nitrate. It is useful for the treatment of antifungal. Contact us for more information.             CEP obtained in 2017 :  R0-CEP 2015-066-Rev 01
  • AMOROLFINE HCl

    Product AMOROLFINE HCl

    PHARMASYNTHESE - INABATA offers a wide range of products which includes amorolfine hcl. It is useful for the treatment of antifungal. Contact us for more information.                        CEP obtained in 2018 : R0-CEP 2016-312-Rev 00
  • DIBUCAINE HCl

    Product DIBUCAINE HCl

    Inabata France offers a wide range of active pharmaceutical ingredients which includes dibucaine hcl. It belongs to anesthesic category. Contact us for more information.CEP obtained in 2007 : R1-CEP 2007-117-Rev 01
  • ESCULINE

    Product ESCULINE

    Inabata France offers a wide range of active pharmaceutical ingredients which includes esculine. It belongs to antiphlogistic category. Contact us for more information.DMF available
  • FENTICONAZOLE NITRATE

    Product FENTICONAZOLE NITRATE

    PHARMASYNTHESE - INABATA offers a wide range of products which includes Fenticonazole Nitrate. It is useful for the treatment of antifungal. 
    Contact us for more information.             
    CEP obtained in 2017 :   R0-CEP 2015-157-Rev 02